Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 7 February 2015, Vol 294, No 7848

Sort by: Newest first Oldest first A-Z Z-A

  • Sydney Crowther dies Subscription

    3 FEB 2015 14:05

    On 19 January 2015, Sydney Crowther MRPharmS, aged 95, of Maddington Place, Shrewton, Salisbury SP3 4JE. Mr Crowther registered with the Society in 1942.

  • MRI brain scan that shows the temporal lobe. An analysis of 129 people with temporal lobe epilepsy and found that genetic control of convulsions was due to a single gene, Sestrin 3 (SESN3)

    Sestrin 3 gene regulates convulsions in epilepsy Subscription

    3 FEB 2015 14:03

    Researchers analysed hippocampal brain tissue samples from 129 people with temporal lobe epilepsy and found that genetic control of convulsions was due to a single gene.

  • Tribute to Sydney Crowther Subscription

    3 FEB 2015 13:56 By Alison Ewing

    When Sydney Crowther passed away on 19 January 2015 at the fine age of 95, it was the end of an era for pharmacy. He was a remarkable man and a passionate “old-school” pharmacist.

  • Anti-VEGF (vascular endothelial growth factor) therapies could help treat tuberculosis, research finds. In the image, SEM of tuberculosis bacteria.

    Anti-VEGF therapies could have role in treating TB Subscription

    3 FEB 2015 13:28

    Bevacizumab, an anti-VEGF drug, was able to normalise granuloma vasculature, improve the delivery of small molecules and decrease hypoxia in a rabbit model of tuberculosis.

  • Pharmacy support for carers

    3 FEB 2015 13:27

    The Pharmaceutical Services Negotiating Committee (PSNC) has produced a resouce to help community pharmacy teams to support carers. Support from healthcare professionals for carers is a priority for NHS England. The resource can be accessed from the PSNC website. 

  • Breakyl side effects

    3 FEB 2015 13:27

    The summary of product characteristics of Breakyl (fentanyl: Meda) has been updated to include the following adverse reactions: fall, flushing and hot flush, diarrhoea, fatigue, respiratory depression, malaise, peripheral oedema, convulsion, hallucination. In addition it is now contraidndicated in treatment of acute pain other than breakthrough pain.

  • Adherence to glucose lowering therapies in diabetes patients falls following a cancer diagnosis, new research finds

    Adherence to diabetes treatments falls after a cancer diagnosis Subscription

    3 FEB 2015 12:22

    Adherence to glucose lowering therapies in diabetes patients falls following a cancer diagnosis.

  • Iclusig warnings

    3 FEB 2015 12:16

    The summary of product characteristics of Iclusig (ponatinib; Ariad) now warns that there is a risk of vascular occlusive events, congestive heart failure and haemorrhage. There is also new information relating to assessment of cardiovascular status and alternative treatment.

  • Maternal, newborn and child health webinars

    3 FEB 2015 12:16

    The International Pharmaceutical Federation’s (FIP) Community Pharmacy Section (CPS) is launching a series of four free webinars to support pharmacists’ efforts in maternal, newborn and child health. The first webinar, which takes place on 18 February 2015 at 11am CET, will give a background to maternal, newborn and child health (MNCH) in the context of the United Nations’ Millennium Development Goals, but particularly in terms of delivering ...

  • Elvanse side effects and administration

    3 FEB 2015 12:15

    The summary of product characteristics for Elvanse (lisdexamfetamine; Shire) has been updated to include constipation and Raynaud’s phenomenon as undesirable effects and anorexia deleted as an undesirable effect. The frequencies of nine other undesirable effects have been updated. In addition there have been changes to the poslogy and administration and interactions sections.  

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.